{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:22:06Z","timestamp":1790418126191,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["13\/RC\/2073_2"],"award-info":[{"award-number":["13\/RC\/2073_2"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejpb.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:39:23Z","timestamp":1636976363000},"page":"309-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model"],"prefix":"10.1016","volume":"169","author":[{"given":"Monique C.P.","family":"Mendon\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M.","family":"O'Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejpb.2021.11.003_b0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.ejpb.2021.11.003_b0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejpb.2021.11.003_b0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","article-title":"Recent advances in the treatment of Huntington\u2019s disease: targeting DNA and RNA","volume":"34","author":"Shannon","year":"2020","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.ejpb.2021.11.003_b0020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.ejpb.2021.11.003_b0025","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (Nano)formulations for delivery of antisense oligonucleotides and Ssmall interfering RNA: focus on the central nervous system","volume":"18","author":"Mendon\u00e7a","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2021.11.003_b0030","first-page":"3","article-title":"The effects of huntingtin-lowering : what do we know so far ?","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.ejpb.2021.11.003_b0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejpb.2021.11.003_b0040","doi-asserted-by":"crossref","first-page":"2001183","DOI":"10.1002\/adhm.202001183","article-title":"Versatile types of cyclodextrin-based nucleic acid delivery systems","volume":"10","author":"Xu","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ejpb.2021.11.003_b0045","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jconrel.2020.11.011","article-title":"Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy","volume":"330","author":"Mousazadeh","year":"2021","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2021.11.003_b0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","article-title":"Cyclodextrins in pharmaceutical formulations I : structure and physicochemical properties, formation of complexes, and types of complex","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2021.11.003_b0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ddr.21452","article-title":"Cyclodextrin complexes: perspective from drug delivery and formulation","author":"Jacob","year":"2018","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2021.11.003_b0060","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijpharm.2017.09.013","article-title":"Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours","volume":"532","author":"Evans","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2021.11.003_b0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/acs.molpharmaceut.6b00646","article-title":"Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3d prostate cancer bone metastases model","volume":"14","author":"Evans","year":"2017","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2021.11.003_b0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2021.11.003_b0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2015.02.007","article-title":"Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis","volume":"71","author":"Gooding","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.11.003_b0080","doi-asserted-by":"crossref","unstructured":"B.M.D.C. Godinho, J.R. Ogier, R. Darcy, C.M.O. Driscoll, J.F. Cryan, Self-assembling modified \u03b2 \u2011 cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington\u2019s disease, Mol. Pharm. 10 (2013) 640\u2013649, doi: 10.1021\/mp3003946.","DOI":"10.1021\/mp3003946"},{"issue":"15","key":"10.1016\/j.ejpb.2021.11.003_b0085","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1039\/D1RA00550B","article-title":"Application progress of RVG peptides to facilitate the delivery of therapeutic agents into the central nervous system","volume":"11","author":"Wang","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2021.11.003_b0090","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cells8090962","article-title":"Mutant huntingtin affects diabetes and Alzheimer\u2019s markers in human and cell models of Huntington\u2019s disease","volume":"8","author":"Chaves","year":"2019","journal-title":"Cells"},{"issue":"25","key":"10.1016\/j.ejpb.2021.11.003_b0095","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1039\/c2ob25490e","article-title":"A click chemistry route to 2-functionalised PEGylated and cationic \u03b2-cyclodextrins: co-formulation opportunities for siRNA delivery","volume":"10","author":"O'Mahony","year":"2012","journal-title":"Org. Biomol. Chem."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.11.003_b0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.12.055","article-title":"A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor","volume":"499","author":"Fitzgerald","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.11.003_b0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejps.2017.11.024","article-title":"Cyclodextrin-siRNA conjugates as versatile gene silencing agents","volume":"114","author":"Malhotra","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2021.11.003_b0110","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1021\/la104590k","article-title":"Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid p K a on cationic lipid-biomembrane interactions","volume":"27","author":"Zhang","year":"2011","journal-title":"Langmuir"},{"issue":"44","key":"10.1016\/j.ejpb.2021.11.003_b0115","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1021\/acs.langmuir.0c02446","article-title":"Investigation of pH-responsiveness inside lipid nanoparticles for parenteral mRNA application using small-angle X-ray scattering","volume":"36","author":"Uebbing","year":"2020","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2021.11.003_b0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-8118-10-16","article-title":"The hCMEC\/D3 cell line as a model of the human blood brain barrier","volume":"10","author":"Weksler","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ejpb.2021.11.003_b0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejpb.2021.04.002","article-title":"In vitro model for predicting the access and distribution of drugs in the brain using hCMEC\/D3 cells","volume":"163","author":"S\u00e1nchez-Dengra","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2021.11.003_b0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejpb.2017.06.018","article-title":"Andrographolide-loaded nanoparticles for brain delivery: formulation, characterisation and in vitro permeability using hCMEC \/ D3 cell line","volume":"119","author":"Guccione","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7149","key":"10.1016\/j.ejpb.2021.11.003_b0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejpb.2021.11.003_b0140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2021.11.003_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.carbpol.2014.10.070","article-title":"Characterization of hydroxypropyl-\u03b2-cyclodextrins with different substitution patterns via FTIR, GC-MS, and TG-DTA","volume":"118","author":"Yuan","year":"2015","journal-title":"Carbohydr. Polym."},{"issue":"4","key":"10.1016\/j.ejpb.2021.11.003_b0150","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1208\/s12249-013-0023-5","article-title":"Molecular inclusion complex of curcumin-\u03b2-cyclodextrin nanoparticle to enhance Curcumin skin permeability from hydrophilic matrix gel","volume":"14","author":"Rachmawati","year":"2013","journal-title":"AAPS PharmSciTech."},{"issue":"13","key":"10.1016\/j.ejpb.2021.11.003_b0155","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/nnm-2018-0139","article-title":"Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases","volume":"13","author":"Ce\u00f1a","year":"2018","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.ejpb.2021.11.003_b0160","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.chempr.2019.07.008","article-title":"Electronic circular dichroism spectroscopy of proteins","volume":"5","author":"Rogers","year":"2019","journal-title":"Chem."},{"key":"10.1016\/j.ejpb.2021.11.003_b0165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11095-014-1545-6","article-title":"Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance","volume":"32","author":"Mc Carthy","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2021.11.003_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-020-00183-7","article-title":"In vitro modeling of the neurovascular unit: advances in the field","volume":"17","author":"Bhalerao","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"2","key":"10.1016\/j.ejpb.2021.11.003_b0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0928-0987(00)00152-4","article-title":"Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug","volume":"12","author":"Gaillard","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.11.003_b0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.09.015","article-title":"A filter-free blood-brain barrier model to quantitatively study transendothelial delivery of nanoparticles by fluorescence spectroscopy","volume":"289","author":"De Jong","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2021.11.003_b0185","unstructured":"B. Srinivasan, A.R. Kolli, M.B. Esch, H.E. Abaci, M.L. Shuler, J.J. Hickman, TEER measuments in cells, 2016, doi: 10.1177\/2211068214561025.TEER."},{"key":"10.1016\/j.ejpb.2021.11.003_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-19522-8","article-title":"A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis","volume":"8","author":"Ribecco-Lutkiewicz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2021.11.003_b0195","doi-asserted-by":"crossref","unstructured":"H.C. Helms, N.J. Abbott, M. Burek, R. Cecchelli, P. Couraud, M.A. Deli, H.J. Galla, I.A. Romero, E. V Shusta, M.J. Stebbins, E. Vandenhaute, B. Weksler, B. Brodin, In vitro models of the blood \u2013 brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use (2016), doi: 10.1177\/0271678X16630991.","DOI":"10.1177\/0271678X16630991"},{"issue":"12","key":"10.1016\/j.ejpb.2021.11.003_b0200","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","article-title":"Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier","volume":"12","author":"Gomes","year":"2017","journal-title":"Nanomedicine"},{"issue":"13","key":"10.1016\/j.ejpb.2021.11.003_b0205","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1096\/fj.04-3458fje","article-title":"Blood-brain barrier-specific properties of a human adult brain endothelial cell line","volume":"19","author":"Weksler","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ejpb.2021.11.003_b0210","unstructured":"I. 10993-5:2009, Biological evaluation of medical devices. Part 5: tests for in vitro cytotoxicity, Int. Organ. Stand. (2009)."},{"key":"10.1016\/j.ejpb.2021.11.003_b0215","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1124\/jpet.104.067512","article-title":"Behavior of a-, b-, and y-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier","volume":"310","author":"Monnaert","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.ejpb.2021.11.003_b0220","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/bm3008633","article-title":"\u03b2-Cyclodextrin-poly (\u03b2 -amino ester) nanoparticles for sustained drug delivery across the blood\u2212brain barrier","volume":"13","author":"Gil","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2021.11.003_b0225","first-page":"1","article-title":"Nanoparticles based on quaternary ammonium chitosan-methyl-\u03b2-cyclodextrin conjugate for the neuropeptide dalargin delivery to the central nervous system: an in vitro study","volume":"13","author":"Migone","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2021.11.003_b0230","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2015.11.056","article-title":"Effect of surface properties on liposomal siRNA delivery","volume":"79","author":"Xia","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2021.11.003_b0235","doi-asserted-by":"crossref","first-page":"eaba3967","DOI":"10.1126\/sciadv.aba3967","article-title":"Targeted exosome coating gene-chem nanocomplex as \u201cnanoscavenger \u201d for clearing a-synuclein and immune activation of Parkinson\u2019s disease","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejpb.2021.11.003_b0240","doi-asserted-by":"crossref","first-page":"146738","DOI":"10.1016\/j.brainres.2020.146738","article-title":"Efficient neuronal targeting and transfection using RVG and transferrin- conjugated liposomes","volume":"1734","author":"dos Santos Rodrigues","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.ejpb.2021.11.003_b0245","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biomaterials.2015.12.021","article-title":"Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype","volume":"82","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2021.11.003_b0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.msec.2017.12.029","article-title":"Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide","volume":"87","author":"Fu","year":"2018","journal-title":"Mater. Sci. Eng. C."},{"issue":"10","key":"10.1016\/j.ejpb.2021.11.003_b0255","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1021\/acsami.7b16096","article-title":"Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona","volume":"10","author":"Zhang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.11.003_b0260","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijpharm.2018.10.011","article-title":"The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system","volume":"552","author":"Xiao","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.11.003_b0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2019.05.010","article-title":"Ligand density on nanoparticles: a parameter with critical impact on nanomedicine","volume":"143","author":"Alkilany","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.ejpb.2021.11.003_b0270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:48:21Z","timestamp":1760546901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":54,"alternative-id":["S0939641121002769"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.11.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}